Cabazitaxel CAS 183133-96-2 Pharmaceutical Powder Cabazitaxel Anti-Cancer Raw Powder

Short Description:

Cabazitaxel is a taxane anti-tumor API. Clinical trials have shown that it can also shrink tumors, slow the growth or spread of tumors, relieve symptoms of prostate cancer and improve the quality of life of patients. Cabazitaxel in combination with prednisone for the treatment of hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen. Hand Bio provides Cabazitaxel CAS 183133-96-2 Pharmaceutical Powder Cabazitaxel Anti-Cancer Raw Powder. For more details, please feel free to consult online.


Product Detail

Product Tags

Product Informations

Name: Cabazitaxel

CAS number: 183133-96-2

Chemical formula: C45H57NO14

Specifications: 99%

Color: white or off-white powder

Source: Semi-synthesized with 10-DAB

Type: APIs

Function

Clinical trials have shown that cabazitaxel can shrink tumors, slow the growth or spread of tumors, and relieve symptoms of prostate cancer.

Hande production capacity

Production cycle: 30-45 days.

Production batch: one batch can produce about 15kg.

Hande production capacity: there is inventory and can be mass produced.

Hande production advantages

Hande,which has built its own GMP production base,has passed the review of laws and regulations of FDA,EDQM,GMP in China,PMDA in Japan,TGA in Australia,South Korea,India,Taiwan,China,Türkiye,Russia,SGS,Dun&Bradley,etc.At the same time,the company is equipped with a research and development team and has successively obtained a number of patents.QC testing room,highly realizing product project testing.

Our Services

1.Products:Provide high-quality,high-purity plant extracts,pharmaceutical raw materials,and pharmaceutical intermediates.

2.Technical services:Customized extracts with special specifications according to customer requirements.

Hande factory

Be the best supplier of raw materials and enterprises with integrity!

Welcome to contact me by sending email to marketing@handebio.com


  • Previous:
  • Next: